We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

133 hedge funds and large institutions have $826M invested in BioCryst Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 25

91% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 11

53% more call options, than puts

Call options by funds: $8.87M | Put options by funds: $5.79M

8% more funds holding

Funds holding: 123 → 133 (+10)

1% more capital invested

Capital invested by funds: $817M → $826M (+$8.86M)

0.25% less ownership

Funds ownership: 92.34% → 92.09% (-0.25%)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
133
Holders Change
+10
Holders Change %
+8.13%
% of All Funds
2.88%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
21
Increased
52
Reduced
25
Closed
11
Calls
$8.87M
Puts
$5.79M
Net Calls
+$3.07M
Net Calls Change
+$2.42M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$12.7M
2
Millennium Management
Millennium Management
New York
+$6.41M
3
State Street
State Street
Massachusetts
+$6.11M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.08M
5
UBS Group
UBS Group
Switzerland
+$3.3M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$17.1M
2
GPP
Great Point Partners
Connecticut
-$14.3M
3
EAM
Eventide Asset Management
Massachusetts
-$8.45M
4
Jennison Associates
Jennison Associates
New York
-$5.98M
5
DM
Deerfield Management
New York
-$3.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
DAFNA Capital Management
California
$4.06M +$291K +34,000 +7%
EP
27
Eversept Partners
New York
$3.36M +$2.13M +248,917 +152%
Goldman Sachs
28
Goldman Sachs
New York
$3.12M +$1.96M +229,103 +148%
Morgan Stanley
29
Morgan Stanley
New York
$2.99M +$1.57M +183,081 +100%
Allianz Asset Management
30
Allianz Asset Management
Germany
$2.73M +$559K +65,325 +24%
JP Morgan Chase
31
JP Morgan Chase
New York
$2.59M -$462K -54,011 -15%
TA
32
Teachers Advisors
New York
$2.58M +$99.6K +11,637 +4%
EI
33
EAM Investors
California
$2.34M -$141K -16,472 -5%
Two Sigma Investments
34
Two Sigma Investments
New York
$2.23M +$2.19M +255,608 +1,420%
EU
35
Emory University
Georgia
$2.16M -$451K -52,732 -17%
Deutsche Bank
36
Deutsche Bank
Germany
$2.03M +$1.28M +148,972 +147%
Bank of America
37
Bank of America
North Carolina
$1.97M +$1.7M +198,375 +461%
CAM
38
ClariVest Asset Management
California
$1.91M +$31.7K +3,700 +2%
LCG
39
Lisanti Capital Growth
New York
$1.8M +$1.9M +221,565 New
Two Sigma Advisers
40
Two Sigma Advisers
New York
$1.58M +$243K +28,400 +17%
EGI
41
EAM Global Investors
California
$1.47M – – –
CS
42
Credit Suisse
Switzerland
$1.39M +$611K +71,362 +72%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$1.37M -$86.9K -10,151 -6%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$1.22M -$2.9K -339 -0.2%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$1.21M +$314K +36,700 +33%
Hudson Bay Capital Management
46
Hudson Bay Capital Management
Connecticut
$1.14M +$85.6K +10,000 +8%
Swiss National Bank
47
Swiss National Bank
Switzerland
$1.14M +$38.5K +4,500 +3%
PPA
48
Parametric Portfolio Associates
Washington
$1.05M +$113K +13,196 +11%
ACH
49
ArrowMark Colorado Holdings
Colorado
$1.02M – – –
AllianceBernstein
50
AllianceBernstein
Tennessee
$947K – – –
1
2
3 4 5

BCRX Hedge Fund Activity: Q1 2019 in Review

133 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2019, worth a combined $826M — up 1.1% from $817M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new BCRX positions and 11 closed out — a net gain of 10 holders — while 52 added to existing stakes and 25 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $12.7M. The largest seller was RA Capital Management, cutting an estimated $17.1M.

  • 133 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2019, up from 123 in Q4 2018.
  • Funds reported $826M of BioCryst Pharmaceuticals stock for Q1 2019, up 1.1% quarter-over-quarter.
  • 21 funds opened new BioCryst Pharmaceuticals positions in Q1 2019 and 11 closed out, a net change of +10 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2019 was Citadel Advisors, an estimated $12.7M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2019 was RA Capital Management, an estimated $17.1M sold.

Based on aggregated 13F filings for Q1 2019.